BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.19
-0.21 (-2.84%)
Apr 16, 2025, 4:00 PM EDT - Market closed
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for BioCryst Pharmaceuticals stock have an average target of 15.67, with a low estimate of 8.00 and a high estimate of 30. The average target predicts an increase of 117.94% from the current stock price of 7.19.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $11 | Buy | Reiterates | $11 | +52.99% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +108.62% | Apr 10, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $18 | Buy | Reiterates | $18 | +150.35% | Mar 3, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $10 → $11 | Buy | Reiterates | $10 → $11 | +52.99% | Feb 25, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $18 | Buy | Reiterates | $18 | +150.35% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
575.38M
from 450.71M
Increased by 27.66%
Revenue Next Year
653.56M
from 575.38M
Increased by 13.59%
EPS This Year
-0.08
from -0.43
EPS Next Year
0.22
from -0.08
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 599.9M | 705.8M | 838.7M | ||
| Avg | 575.4M | 653.6M | 745.8M | ||
| Low | 539.0M | 591.9M | 624.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 33.1% | 22.7% | 28.3% | ||
| Avg | 27.7% | 13.6% | 14.1% | ||
| Low | 19.6% | 2.9% | -4.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.05 | 0.60 | 1.58 | ||
| Avg | -0.08 | 0.22 | 0.94 | ||
| Low | -0.22 | -0.08 | 0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 620.5% | ||
| Avg | - | - | 330.9% | ||
| Low | - | - | 142.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.